MyFinsight
Home
Blog
About
Issuance of class a
ordinary shares and...
$189,759K
Issuance of class a
ordinary shares under the...
$44,312K
Proceeds from options
exercised-Equity Incentive Plan
$551K
Proceeds from maturities
of short-term...
$59,070K
(-83.16%↓ Y/Y)
Net cash flow
provided by financing...
$234,622K
(220.86%↑ Y/Y)
Net cash flow
provided by investing...
$322K
(-99.78%↓ Y/Y)
Effect of movements in
exchange rates on cash...
$29K
(-97.77%↓ Y/Y)
Canceled cashflow
$58,748K
Net change in cash
and cash...
$179,415K
(42.11%↑ Y/Y)
Canceled cashflow
$55,558K
Prepaid expenses
-$6,510K
(-282.35%↓ Y/Y)
Accrued expenses and
other current...
$3,794K
(212.65%↑ Y/Y)
Share-based compensation
expense
$2,546K
(-54.53%↓ Y/Y)
Depreciation and
amortization
$896K
(-20.00%↓ Y/Y)
Other non-cash items
-$19K
(-101.57%↓ Y/Y)
Net periodic
pension benefit gain...
$9K
(200.00%↑ Y/Y)
Operating lease
right-of-use assets
-$8K
Other non-current
assets
-$1K
(-100.06%↓ Y/Y)
Purchase of short-term
marketable debt securities
$58,748K
(-71.51%↓ Y/Y)
Net cash flow used in
operating activities
-$55,558K
(40.05%↑ Y/Y)
Canceled cashflow
$13,783K
Net loss
-$61,806K
Trade and other
payables
-$6,342K
(-178.42%↓ Y/Y)
Other receivables
$798K
(40.99%↑ Y/Y)
Operating lease
liabilities
-$395K
(11.04%↑ Y/Y)
Back
Back
Cash Flow
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)
source: myfinsight.com